{"id":14125,"date":"2026-06-01T21:00:00","date_gmt":"2026-06-01T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=81fd2fd9d273f73a5f99a11508bd60be"},"modified":"2026-06-01T21:00:00","modified_gmt":"2026-06-01T19:00:00","slug":"theraclion-announces-the-success-of-the-first-international-hifu-congress-in-parma-where-promising-preliminary-results-from-its-sonovein-speedpulse-were-presented","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=14125","title":{"rendered":"Theraclion Announces the Success of the First International HIFU Congress in Parma, Where Promising Preliminary Results From Its Sonovein\u00ae SpeedPulse Were Presented"},"content":{"rendered":"

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:<\/p><\/a><\/a><\/a><\/a>

\nTheraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a robotic platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicose veins (the \u201cCompany\u201d), announces the success of the first international HIFU congress, held in Parma on May 22 and 23, 2026, during which promising preliminary results from the clinical study conducted in Prague with its next-generation Sonovein\u00ae SpeedPulse were presented.<\/p>

\nThe Parma congress confirms the growing interest of the phlebology community in Sonovein\u00ae<\/b><\/p>

\nThe Third International Days of Phlebology<\/i> congress, held in Parma, Italy, on May 22 and 23, 2026, and presented as the first HIFU congress, allowed the company to present its Sonovein\u00ae technology to the international phlebology community.<\/p>

\nDedicated HIFU sessions and roundtable discussions were organized during the congress, during which 13 Sonovein\u00ae users and key opinion leaders shared routine clinical practice results, covering hundreds of patients, different types of veins and several years of follow-up.<\/p>

\nMore than one hundred healthcare professionals visited Theraclion\u2019s booth during the congress, confirming the growing interest of the scientific community in the potential of non-invasive HIFU treatment enabled by Sonovein\u00ae.<\/p>

\nSpeedPulse: treatments performed in less than 30 minutes thanks to acoustic and robotic advances<\/b><\/p>

\nDuring this event, preliminary results from the SpeedPulse study, initiated and conducted by Professor Jaroslav Strej\u010dek in Prague, were presented. This study aims to evaluate a new prototype integrating advanced acoustic and robotic technologies designed to significantly accelerate treatment delivery and make the device easier to use.<\/p>

\nEarly observations show a major reduction in procedure duration, with treatments now performed in less than 30 minutes, together with improved physician ergonomics enabled by enhanced robotic range of motion and additional degrees of freedom. These advances address a key adoption challenge: making treatment faster, simpler and easier to integrate into daily practice.<\/p>

\n\u201cThis study illustrates the remarkable expertise and progress achieved by our engineering and R&D teams<\/i>,\u201d said Martin Deterre, CEO of Theraclion. \u201cIt demonstrates our ability to continuously improve the Sonovein\u00ae platform to make treatment faster, easier to use and easier to integrate into physicians\u2019 daily practice. The gains observed with SpeedPulse validate several years of development in acoustics and robotics. Our ongoing work on artificial intelligence should allow us to go even further, by further reducing treatment times and improving the ergonomics of the device. We are eager to move on to the next stages of development, validation and industrialization in order to bring these new features to our users in the coming years.<\/i>\u201d<\/p>

\nProfessor Jaroslav Strej\u010dek, Principal Investigator of the study in Prague, commented:<\/p>

\n\u201cThe speed improvements observed with this new prototype are very impressive. We are seeing treatments performed much faster and more smoothly than before, while maintaining the advantages of a completely non-invasive approach. These are very encouraging early clinical results<\/i>.\u201d<\/p>

\nTheraclion emphasizes that the current prototype remains under clinical evaluation and is not yet commercially available. Additional development work and regulatory approvals will be required before any potential market introduction.<\/p>

\nAbout Theraclion<\/b><\/p>

\nTheraclion is a French MedTech company developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.\nHigh Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and allows patients to resume normal activities immediately. HIFU concentrates therapeutic ultrasound on an internal focal point from outside the body.\nTheraclion is developing Sonovein\u00ae, a robotic HIFU platform for varicose vein treatment, CE marked under the MDR (EU 2017\/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein\u00ae has been adopted by more than a dozen centers worldwide and used in over 4,000 procedures. In the U.S., Sonovein\u00ae is not yet available for sale.\nBased in Malakoff (Paris), Theraclion\u2019s team comprises around 35 people.<\/p>

\nFor more information, please visit www.theraclion.com<\/a> and follow the <\/b>LinkedIn account<\/b><\/a>.\n<\/b>Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme\nTicker: ALTHE - ISIN Code: FR0010120402 LEI: 9695007X7HA7A1GCYD29<\/p> Contacts<\/b>

\nTheraclion<\/b>Martin Deterre\nChief Executive Officer\ninvestors@theraclion.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

MALAKOFF, France–(BUSINESS WIRE)–Regulatory News:
\nTheraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a robotic platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicos…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-14125","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14125"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14125\/revisions"}],"predecessor-version":[{"id":14126,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/14125\/revisions\/14126"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}